• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Future Prospects of Global Personalized Medicine Market 2012-2016 - Product Image

Future Prospects of Global Personalized Medicine Market 2012-2016

  • Published: July 2013
  • Region: Global
  • 60 Pages
  • TechNavio

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Evotec AG
  • Johnson & Johnson
  • PerkinElmer Inc.
  • MORE

The analysts forecast the Global Personalized Medicine market 2012-2016 to grow at a CAGR of 12.07 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Targeted Biologics segment. The Global Personalized Medicine market has also been witnessing an increase in the number of mergers ad acquisitions. However, the low awareness of personalized medicine in developing countries could pose a challenge to the growth of this market.

The report, the Future Prospects of Global Personalized Medicine Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Personalized Medicine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include Abbott Laboratories, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A.

The other vendors mentioned in the report are Affymetrix Inc., Agendia B.V., Agilent READ MORE >

01. Executive Summary
02. List of Abbreviations
03. Introduction
04. Market Research Methodology
Market Research Process
Research Design
Research Methodology
05. Scope of the Report
Market Overview
Product Offerings
06. Market Landscape
06.1 Market Size and Forecast
06.2 Key Market Segmentation
Segmentation by Product Types
Global Targeted Biologics Market
Global Proteomics and Genomics Market
Segmentation by Application Technologies
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Key Leading Countries
USA
Germany
Japan
09. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Key Vendor Analysis
16.1 Abbott Laboratories
Business Overview
Key Information
SWOT Analysis
16.2 AstraZeneca plc
Business Overview
Key Information
SWOT Analysis
16.3 F. Hoffmann-La Roche Ltd.
Business Overview
Key Information
SWOT Analysis
16.4 Novartis AG
Business Overview
Key Information
SWOT Analysis
16.5 Pfizer Inc.
Business Overview
Key Information
SWOT Analysis
16.6 Sanofi S.A.
Business Overview
Key Information
SWOT Analysis
17. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Personalized Medicine Market 2012-2016 (US$ billion)
Exhibit 3: Major Products and Indications in the Global Personalized Medicine Market
Exhibit 4: Global Personalized Medicine Market by Product Types
Exhibit 5: Global Targeted Biologics Market 2012-2016 (US$ billion)
Exhibit 6: Global Proteomics and Genomics Market 2012-2016 (US$ billion)
Exhibit 7: Global Personalized Medicine Market by Application Technologies
Exhibit 8: Global Personalized Medicine Market by Geographical Segmentation 2012
Exhibit 9: Business Segmentation of Abbott Laboratories
Exhibit 10: Business Segmentation of AstraZeneca plc
Exhibit 11: Business Segmentation of Hoffmann-La Roche Ltd.
Exhibit 12: Business Segmentation of Novartis AG
Exhibit 13: Business Segmentation of Pfizer Inc.
Exhibit 14: Business Segmentation of Sanofi S.A.

Commenting on the report, an analyst from the team said: “Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.”

According to the report, one of the key drivers in this market is the significant growth of the Targeted Biologics segment. This segment is one of the significant segments of personalized medicine and is expected to signify about 25 percent of the commercialized drugs during the forecast period.

Further, the report states that one of the major challenges is patients' limited awareness about personalized medicines in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicines.

The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Affymetrix Inc., Agendia B.V., Agilent Technologies Inc., Amgen Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, BG Medicine Inc., Biocartis S.A., Biogen Idec Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Celgene Corp., Daiichi Sankyo Co. Ltd., Danaher Corp., Eli Lilly and Co., Evotec AG, GE Healthcare Ltd., Genelex Corp., GlaxoSmithKline plc, Hologic Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, Life Technologies Corp., Merck KGaA, Mitsubishi Tanabe Pharma Corp., Myriad Genetics Inc., PerkinElmer Inc., Quest Diagnostics Inc., Siemens Healthcare, Sigma-Aldrich Corp., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Transgenomic Inc.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Abbott Laboratories
- Affymetrix Inc.
- Agendia B.V.
- Agilent Technologies Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- BG Medicine Inc.
- Baxter International Inc.
- Bayer AG
- Biocartis S.A
- Biogen Idec Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co.
- Celgene Corp.
- Daiichi Sankyo Co. Ltd.
- Danaher Corp.
- Eli Lilly and Co.
- Evotec AG
- F. Hoffmann-La Roche Ltd.
- GE Healthcare Ltd.
- Genelex Corp.
- GlaxoSmithKline plc
- Hologic Inc.
- Johnson & Johnson
- Laboratory Corporation of America Holdings
- Life Technologies Corp.
- Merck KGaA
- Mitsubishi Tanabe Pharma Corp.
- Myriad Genetics Inc.
- Novartis AG
- Novartis AG
- PerkinElmer Inc.
- Pfizer Inc.
- Pfizer Inc.
- Quest Diagnostics Inc.
- Sanofi S.A.
- Sanofi S.A.
- Siemens Healthcare
- Sigma-Aldrich Corp.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Transgenomic Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos